Leish-111f + MPL-SE vaccine

BIOLOGICAL4 trials

Sponsors

Access to Advanced Health Institute (AAHI)

Conditions

Cutaneous LeishmaniasisLeishmaniasis, CutaneousLeishmaniasis, Mucocutaneous

Phase 1

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

CompletedNCT00111514

Access to Advanced Health Institute (AAHI)Leishmaniasis, Mucocutaneous

Start: 2004-07-31End: 2006-05-31Target: 48Updated: 2007-02-15

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

CompletedNCT00111553

Access to Advanced Health Institute (AAHI)Leishmaniasis, Cutaneous

Start: 2004-10-31End: 2006-08-31Target: 45Updated: 2007-02-15

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

CompletedNCT00121849

Access to Advanced Health Institute (AAHI)Cutaneous Leishmaniasis

Start: 2005-08-31End: 2006-02-28Target: 12Updated: 2006-05-05

Phase 2

Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite

CompletedNCT00121862

Access to Advanced Health Institute (AAHI)Cutaneous Leishmaniasis

Start: 2005-08-31End: 2006-03-31Target: 60Updated: 2006-05-05